Omonta applies AI agents to personalized tumor analysis

Omonta is building a platform that uses LLM and AI agents, along with protein models, to help patients and clinicians analyze a tumor’s biology and identify treatment options that could be missed otherwise. The company describes its system as a link between deep genomic data and clinical decisions.

The company says conventional sequencing panels typically cover about 50–500 genes, compared with a total gene space of more than 20,000. Omonta’s current model is direct-to-patient, direct-to-consumer, or direct to sponsors; it says earlier sequencing and informatics could improve median life expectancy and reduce insurers’ costs. Omonta predicts insurance coverage for such services will eventually expand.

Omonta says it launched about a month earlier and had $319,000 in MRR and more than 150 patients. It identifies infrastructure as the main bottleneck, noting that genomic datasets can range from 30 to 200 gigabytes while legacy systems often handle megabytes of data outside imaging.